Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Urigen Pharmaceuticals has amended its licensing agreement with the University of California at San Diego for intellectual property covering the company's URG101 program for painful bladder syndrome.
Subscribe to our email newsletter
William Garner, CEO of Urigen Pharmaceuticals, said: “In co-operation with the University of California at San Diego (UCSD), we have amended the annual license payments to ensure that we are in compliance with our obligations.
“Amending this license with UCSD is an important step in re-organizing and re-focusing our efforts to enhance shareholder value.”